Insider Trading February 24, 2026

Innospec Director Larry Padfield Disposes of 1,030 Shares, Exercises Options and Sees RSUs Vesting

Padfield sold shares worth $84,296, exercised options and had restricted stock units vesting; company valuation metrics noted

By Nina Shah IOSP
Innospec Director Larry Padfield Disposes of 1,030 Shares, Exercises Options and Sees RSUs Vesting
IOSP

Innospec INC director Larry Padfield completed a set of transactions in late February 2026 that included the sale of 1,030 common shares, the exercise of options for an identical number of shares, and the vesting of restricted stock units. The trades occurred as the specialty chemicals firm trades below a referenced fair value estimate and continues a long record of dividend increases.

Key Points

  • Padfield sold 1,030 shares of Innospec common stock on February 20, 2026 at $81.8409 per share for total proceeds of $84,296.
  • On February 20, 2026 Padfield exercised options to acquire 1,030 shares at $44.18 per share for a total cost of $45,505.
  • On February 23, 2026 Padfield was recorded as acquiring 1,539 restricted stock units with a reported value of $0 that vest in full on February 23, 2029; Innospec trades below its InvestingPro Fair Value and has raised its dividend for 12 consecutive years.

Director Larry Padfield of Innospec INC (NASDAQ:IOSP) executed multiple equity transactions in February 2026, according to regulatory filings. On February 20, 2026, Padfield sold 1,030 shares of Innospec common stock at a per-share price of $81.8409, producing gross proceeds of $84,296.

On the same day, Padfield also exercised stock options to buy 1,030 shares of Innospec common stock at an exercise price of $44.18 per share, for a total exercise cost of $45,505. Those exercised options and the contemporaneous sale are recorded in the filings as separate actions completed on February 20, 2026.

Several days later, on February 23, 2026, Padfield was recorded as acquiring 1,539 shares of Innospec common stock that carried a reported value of $0 in the filing. Those shares are restricted stock units granted as part of Padfield's compensation for service as a non-employee director and are scheduled to vest in full on February 23, 2029.

The transactions occurred while Innospec, a specialty chemicals company with a market capitalization of $1.96 billion, was trading at $79.30 per share. The filing commentary notes that this trading price is below the company's InvestingPro Fair Value estimate, suggesting the stock may be undervalued according to that metric.

Additional company context included in the filings highlights a long-running record of dividend increases. According to InvestingPro Tips cited in the disclosure, Innospec has raised its dividend for 12 consecutive years, a datapoint that underscores a pattern of shareholder distributions.

The set of actions by Padfield - sale, option exercise, and restricted stock unit vesting - are documented in the corporate filings and reflect routine director-level equity activity. The filings specify dates, quantities, prices and the vesting schedule for the restricted awards without providing further commentary on future trading plans or corporate strategy.


Clear summary

Director Larry Padfield sold 1,030 Innospec shares on February 20, 2026 for $81.8409 each, exercised options for 1,030 shares at $44.18 per share on the same date, and on February 23, 2026 had 1,539 restricted stock units recorded as acquired with a zero reported value that vest in full on February 23, 2029. At the time, Innospec had a market cap of $1.96 billion and was trading at $79.30, below its InvestingPro Fair Value estimate. The company has also increased its dividend for 12 consecutive years according to InvestingPro Tips.

Risks

  • Insider transactions do not by themselves indicate future company performance; the filings show sales, option exercises and RSU vesting but do not disclose any future trading intentions - relevant to equity investors and the specialty chemicals sector.
  • The market price at the time of the transactions was below the referenced InvestingPro Fair Value, which highlights valuation uncertainty; this matters to investors assessing relative value in the chemicals and materials sector.
  • Restricted stock units vest on a future date (February 23, 2029), introducing timing uncertainty for potential future dilution or director-related equity activity that could affect shareholder metrics in the long term.

More from Insider Trading

ImmunityBio Director Sells $250,000 in Stock as Company Posts Strong ANKTIVA Revenue Gains Feb 24, 2026 Palantir CEO Disposes $65.9M of Class A Shares, Converts Class B Stock Amid Corporate Momentum Feb 24, 2026 Palantir Director Sells $43.7M in Class A Shares as Stock Trades Below Peak Levels Feb 24, 2026 ImmunityBio Director Executes $1.78M Stock Sales as ANKTIVA Revenue Accelerates Feb 24, 2026 KalVista CFO Disposes $27,506 in Stock as Company Posts Strong EKTERLY Launch Metrics Feb 24, 2026